Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

PAS 2024 Insights: Using Technology to Overcome Vaccine Hesitancy

Joe Real

CAR T-Cell Therapy in Autoimmune Disorders

Vanderbilt University Medical Center (VUMC)

O. Oluwole

COVID-19 Vaccine Effectiveness Against Long COVID in Children

Hanieh Razzaghi

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Rush University Medical Center

C. Brunstein

Travel Medicine Update

Icahn School of Medicine at Mount Sinai

D. Caplivski

The Expanding World of CAR T-Cell Therapy

UNC Lineberger Comprehensive Cancer Center

F. Brianne Buchanan

Selection and Sequencing of Chronic GVHD Therapy

Rush University Medical Center

S. Kosuri

CAR NK Cells: Next Generation Cell Therapies for Cancer

University of Colorado Cancer Center

K. Rezvani

Updates on Immunization - COVID-19, Influenza, and RSV

Scott Roberts

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

Correlation of PROs and Organ Response in Belumosudil-Treated cGVHD:…

Levanto Schachter

Age Limits in Stem Cell Transplants and Cell Therapy

Vanderbilt University Medical Center (VUMC)

R. Jayani

Understanding New Strategies to Prevent and Manage Chronic GVHD

2024 ASCO® Annual Meeting Insights Hub

B. Hamilton

Unmet Needs in GvHD and the Role of Axatilimab

Jose Perez Simon